CRISPR Pill May Be Key in Fight Against Antibiotic Resistance – Singularity Hub
Singularity Hub |
CRISPR Pill May Be Key in Fight Against Antibiotic Resistance
Singularity Hub Even since Alexander Fleming stumbled across penicillin—the first antibiotic drug—scientists knew our fight with evolution was on. Most antibiotics work by blocking biological processes that allow bacteria to thrive and multiply. With prolonged, low … Quick, Sensitive Diagnostic Tests with CRISPRTechnology Networks |
Controlled Environments Magazine |
Nanoparticle Vaccine Shows Potential as Immunotherapy to Fight Multiple Cancer Types
Controlled Environments Magazine Researchers from UT Southwestern Medical Center have developed a first-of-its-kind nanoparticle vaccine immunotherapy that targets several different cancer types. The nanovaccine consists of tumor antigens – tumor proteins that can be recognized by the … Newly Discovered Nanoparticle Vaccines May Defeat Multiple Cancers [Video]University Herald |
Controlled Environments Magazine |
Nanoparticle Vaccine Shows Potential as Immunotherapy to Fight Multiple Cancer Types
Controlled Environments Magazine Researchers from UT Southwestern Medical Center have developed a first-of-its-kind nanoparticle vaccine immunotherapy that targets several different cancer types. The nanovaccine consists of tumor antigens – tumor proteins that can be recognized by the … First-Ever Nanoparticle Vaccine Fights Different Types Of Cancer [VIDEO]University Herald |
Science Business |
World’s first gene therapy to be withdrawn in from market in Europe
Science Business Four and a half years after making history and getting European Medicines Agency approval for the first gene therapy in a regulated market, uniqure NV is throwing in the towel and will not apply for the license to be renewed when its expires on 25 October. Gene Therapy 2017 News: First Gene Therapy Drug Worth $1M, Withdrawn Due to Lack of DemandChristian Post EMA designates uniQure’s gene therapy for hemophilia a priorityLabiotech.eu (blog) UniQure’s haemophilia B therapy picks up PRIME statusPharmaTimes |
Science Business |
World’s first gene therapy to be withdrawn in from market in Europe
Science Business Four and a half years after making history and getting European Medicines Agency approval for the first gene therapy in a regulated market, uniqure NV is throwing in the towel and will not apply for the license to be renewed when its expires on 25 October. Gene Therapy 2017 News: First Gene Therapy Drug Worth $1M, Withdrawn Due to Lack of DemandChristian Post EMA designates uniQure’s gene therapy for hemophilia a priorityLabiotech.eu (blog) UniQure’s haemophilia B therapy picks up PRIME statusPharmaTimes |